Could stem cells help stroke patients recover? new trial launches

NCT ID NCT07371624

Recruiting now Disease control Sponsor: Tasly Pharmaceutical Group Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a single injection of stem cells (B2065) given within 36 hours of a stroke. The goal is to see if it is safe and might help patients recover better. Fifty-four adults with moderate to severe stroke will receive either the stem cells or a placebo, and be followed for two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: B2065 (allogeneic adipose-derived mesenchymal stromal cells)
What this could lead to: If it works, this could point toward a treatment that helps people recover better after a stroke by reducing brain damage.
What could go wrong: This is an early-phase trial with only 54 participants, so it is not yet proven to work. There may be side effects like infusion reactions or other unknown risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE

Contacts and locations

Show contact details

Locations

Beijing Tiantan Hospital, Capital Medical University
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.